Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phase III Survival Benefit Boosts Imbruvica’s Profile Ahead Of FDA’s CLL Decision

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

RESONATE study is halted after Pharmacyclics/Janssen’s Imbruvica shows a survival benefit as a monotherapy compared to GlaxoSmithKline’s Arzerra. Analysts expect results will pave way for off-label use ahead of FDA’s approval in CLL, though a delay for official clearance is possible.


Related Content

The Next Phase In Oncology: FDA’s Pazdur Has New Vision For Drug Development
Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts